Navigation Links
Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010

BOSTON, Jan. 27, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company generated revenues during the three months ended December 31, 2010 in the amount of $90,005. The revenue for the three month period is a result of instrument sales to over fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for the Company's ISO 13485 quality management system (QMS) initiative. The ISO QMS initiative is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union. Solos recently announced the approval of its 2011 recapitalization plan, which allows greater flexibility to utilize the assets of the Company to raise the necessary capital to achieve the aforementioned goals.

"As an innovative HealthCare instrument company, Solos continues to position itself to take advantage of the ever increasing demand of the medical industry," stated Bob Segersten, President of Solos Endoscopy, Inc. "Our portfolio is centered on instruments like the MammoView Breast Endoscopy System that are designed to support a wide range of options from screening and diagnosis, to treatment and management of medical conditions."

The Company expects to post its full unaudited financial results for the three months ended December 31, 2010 on the OTC Markets Group website within in the next sixty days.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Trends toward Strong Continued Growth in 2011
2. Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
3. Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
4. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
5. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
6. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
7. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
8. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
9. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
10. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
11. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):